Evidence map›Paper›PMID 37497018›Full record

ArticleCrohn's & colitis 3602023

Economic and Clinical Burden of Herpes Zoster Among Patients With Inflammatory Bowel Disease in the United States.

David Singer, Philippe Thompson-Leduc, Deepshekhar Gupta, Sara Poston, Wendy Y Cheng, Siyu Ma, John E Pawlowski, Mei Sheng Duh, Francesca Devine, Azeem Banatwala and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Crohn's & colitis 360, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

David SingerGSK, US Health Outcomes and Epidemiology-Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA 19104, USA.ORCID https://orcid.org/0000-0001-8008-8003
Philippe Thompson-LeducAnalysis Group, Inc., Health Economics and Outcomes Research, 1190 Avenue des Canadiens-de-Montréal, Suite 1500, Montréal, QC H3B 0G7, Canada.ORCID https://orcid.org/0000-0001-9047-3941
Deepshekhar GuptaAnalysis Group, Inc., Health Economics and Outcomes Research, 1010 El Camino Real, Suite 310, Menlo Park, CA 94025, USA.ORCID https://orcid.org/0000-0002-3695-3546
Sara PostonGSK, US Health Outcomes and Epidemiology-Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA 19104, USA.ORCID https://orcid.org/0000-0003-4735-057X
Wendy Y ChengAnalysis Group, Inc., Health Economics and Outcomes Research, 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA.ORCID https://orcid.org/0000-0002-8281-2496
Siyu MaGSK, US Health Outcomes and Epidemiology-Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA 19104, USA.ORCID https://orcid.org/0000-0001-7269-2884
John E PawlowskiGSK, Medical Affairs, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA 19104, USA.ORCID https://orcid.org/0000-0003-3857-7924
Mei Sheng DuhAnalysis Group, Inc., Health Economics and Outcomes Research, 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA.ORCID https://orcid.org/0000-0001-5035-6687
Francesca DevineAnalysis Group, Inc., Health Economics and Outcomes Research, 151 West 42nd Street, 23rd Floor, New York, NY 10036, USA.ORCID https://orcid.org/0000-0001-9689-4659
Azeem BanatwalaAnalysis Group, Inc., Health Economics and Outcomes Research, 333 South Hope Street, 27th Floor, Los Angeles, CA 90071, USA.ORCID https://orcid.org/0000-0002-3464-4897
Emma BernsteinAnalysis Group, Inc., Health Economics and Outcomes Research, 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA.ORCID https://orcid.org/0000-0001-5683-6876
Francis A FarrayeMayo Clinic, Division of Gastroenterology and Hepatology, 4500 San Pablo Road, Jacksonville, FL 32224, USA.ORCID https://orcid.org/0000-0001-6371-2441
Analysis Group (United States) · USBaylor University · USFMC (United States) · USGroup for Research in Decision Analysis · CAHealth Outcomes Solutions (United States) · USJacksonville College · USTufts Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with ulcerative colitis (UC) or Crohn's disease (CD) are at increased risk of herpes zoster (HZ); however, relevant cost and healthcare resource utilization (HCRU) data are limited. Methods: We estimated HCRU (hospitalization, emergency department [ED], and outpatient visits) and costs in patients with UC or CD, with and without HZ, using administrative claims data (October 2015-February 2020). HCRU and costs (2020 US dollars) were compared at 1 month, 1 quarter, and 1 year after the index date, using propensity score adjustment and generalized linear models. Results: In total, 20 948 patients were included: UC+/HZ+ ( Conclusions: HZ is associated with increased HCRU and costs in patients with UC and CD, especially shortly after diagnosis.

Indexed as

costsCrohn’s diseasehealthcare resource utilizationherpes zosterulcerative colitis

Identifiers

PMID37497018
PMCPMC10368335
OpenAlexW4384281358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.